Vicriviroc in Combination Treatment With an Optimized ART [antiretroviral] Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057).

Trial Profile

Vicriviroc in Combination Treatment With an Optimized ART [antiretroviral] Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Vicriviroc (Primary)
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Acronyms VICTOR-E2
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top